Investors

OPPORTUNITIES FOR INVESTORS

Bridge Therapeutics’ lead investigational drug is a patent protected combination of a partial opioid agonist (Buprenorphine) and an NSAID pain reliever (Meloxicam). Bridge is currently pursuing approval for BT-205 in the United States (FDA) and Europe (EMA).

Please fill out the form below to contact us and learn more about how this new synergistic combination can provide better pain management and less risk of addiction or overdose compared to current therapies for chronic pain.